VPC-70063

VPC-70063 is a potent Myc-Max inhibitor with an IC50 value of 8.9 μM for Myc-Max transcriptional activity inhibition. VPC-70063 reduces UBE2C promotor activity and AR-V7 levels, and induces PARP cleavage. VPC-70063 induces apoptosis and blocks Myc-Max interactions with DNA. VPC-70063 can be used for researching anticancer[1].

Product Specifications

CAS Number

[13571-44-3]

UNSPSC

12352005

Target

Apoptosis; c-Myc; PARP

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vpc-70063.html

Purity

99.92

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

FC(F)(C1=CC(NC(NCC2=CC=CC=C2)=S)=CC(C(F)(F)F)=C1)F

Molecular Formula

C16H12F6N2S

Molecular Weight

378.34

References & Citations

[1]Carabet LA, et al. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. Eur J Med Chem. 2018 Dec 5;160:108-119.